What Spore.Bio does
Spore.Bio's Transformer-based Multimodal Spectral Imaging technology detects, quantifies and identifies microorganisms directly, without the culturing, enrichment or dyes traditional microbiology testing requires, cutting results from days to minutes, the company says. It serves the food, beverage, cosmetics, pharmaceutical and water-testing industries and was selected for Google.org's $20M AI for Science fund. Spore.Bio was founded in Paris in 2022 by Maxime Mistretta and Amine Raji. It raised a $23M ($22M) Series A on February 20, 2025, led by Singular, according to TechCrunch and Tech.eu.
Spore.Bio is a research tool on Falcoscan. AI spectral imaging that detects microorganisms without lab culturing. Falcoscan rates Spore.Bio with an Opportunity score of 78/100, a Saturation score of 14/100, and a Wrapper-risk score of 15/100. Market signal: rising. Spore.Bio is founded in 2022, currently at Series_a stage. Pricing: Paid.